Cancer patients in Serbia are experiencing growing anxiety as access to a potentially life-extending innovative therapy remains delayed. The treatment, secured through an agreement between the Republic Health Insurance Fund (RFZO) and AstraZeneca over two months ago, is still unavailable. Bureaucratic hurdles and the timing coinciding with ongoing election preparations are suspected of contributing to the delay. Patients report their conditions are worsening while awaiting the new therapy, creating significant distress. The RFZO has not provided a clear timeline for the treatment’s implementation, fueling concerns about equitable access to healthcare. Advocacy groups are calling for urgent action to prioritize patient needs and expedite the process, independent of the political climate. The situation highlights potential conflicts between political processes and critical healthcare provisions.